HK1067981A1 - (1-4-piperidinyl) benzimidazole derivatives usefulas histamine h3 antagonists - Google Patents

(1-4-piperidinyl) benzimidazole derivatives usefulas histamine h3 antagonists

Info

Publication number
HK1067981A1
HK1067981A1 HK05100695A HK05100695A HK1067981A1 HK 1067981 A1 HK1067981 A1 HK 1067981A1 HK 05100695 A HK05100695 A HK 05100695A HK 05100695 A HK05100695 A HK 05100695A HK 1067981 A1 HK1067981 A1 HK 1067981A1
Authority
HK
Hong Kong
Prior art keywords
usefulas
histamine
piperidinyl
antagonists
benzimidazole derivatives
Prior art date
Application number
HK05100695A
Other languages
English (en)
Inventor
Zeng Qingbei
Aslanian Michael
Boyce Christopher
Cao Jianhua
Kozlowski Joseph
Mangiaracina Pietro
Mc Cormick Kevin
Mutahi Mwangi
Rosenblum Stuart
Shih Neng-Yang
Solomon Daniel
Tom Wing
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1067981A1 publication Critical patent/HK1067981A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05100695A 2002-04-18 2005-01-26 (1-4-piperidinyl) benzimidazole derivatives usefulas histamine h3 antagonists HK1067981A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18
PCT/US2003/011672 WO2003088967A1 (en) 2002-04-18 2003-04-16 (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
HK1067981A1 true HK1067981A1 (en) 2005-04-22

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100695A HK1067981A1 (en) 2002-04-18 2005-01-26 (1-4-piperidinyl) benzimidazole derivatives usefulas histamine h3 antagonists

Country Status (27)

Country Link
EP (1) EP1499316B1 (de)
JP (1) JP4384918B2 (de)
KR (1) KR100827470B1 (de)
CN (1) CN100522166C (de)
AR (1) AR040405A1 (de)
AT (1) ATE389406T1 (de)
AU (1) AU2003223627B2 (de)
BR (1) BR0309348A (de)
CA (1) CA2481940A1 (de)
CY (1) CY1110363T1 (de)
DE (1) DE60319813T2 (de)
DK (1) DK1499316T3 (de)
EC (1) ECSP045367A (de)
ES (1) ES2301791T3 (de)
HK (1) HK1067981A1 (de)
IL (1) IL164584A (de)
MX (1) MXPA04010173A (de)
NO (1) NO20045002L (de)
NZ (1) NZ535763A (de)
PE (1) PE20040684A1 (de)
PL (1) PL373889A1 (de)
PT (1) PT1499316E (de)
RU (1) RU2323935C2 (de)
SI (1) SI1499316T1 (de)
TW (1) TW200306183A (de)
WO (1) WO2003088967A1 (de)
ZA (1) ZA200407984B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007513A (es) 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
PL1615909T3 (pl) 2003-04-23 2009-01-30 Glaxo Group Ltd Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych
ES2686357T3 (es) 2004-06-17 2018-10-17 Cytokinetics, Inc. Compuestos, composiciones y procedimientos
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
CA2595157A1 (en) * 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
WO2007002057A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
WO2007039462A2 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
CN101426777A (zh) 2005-12-21 2009-05-06 先灵公司 用作组胺h3拮抗剂的苯氧基哌啶及其类似物
JP2009523150A (ja) * 2006-01-13 2009-06-18 エフ．ホフマン−ラ ロシュ アーゲー シクロヘキシルピペラジニルメタノン誘導体及びｈ３受容体調節剤としてのそれらの使用
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
EP2188288A1 (de) * 2007-09-11 2010-05-26 Abbott Laboratories Octahydropyrrolo[3,4-b]pyrrol-n-oxide
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
EP2519522B1 (de) 2009-12-30 2014-09-24 ArQule, Inc. Substituierte imidazopyridinyl-aminopyridin-verbindungen
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
BR112013033182A2 (pt) 2011-06-24 2016-09-06 Arqule Inc compostos imidazopiridinil-aminopiridina substituída
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
US10118900B2 (en) 2015-08-25 2018-11-06 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as CB-1 inverse agonists
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
MXPA03002448A (es) * 2000-09-20 2003-06-19 Schering Corp Eimidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina.
EP1494671B1 (de) * 2002-04-18 2011-10-19 Schering Corporation 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten

Also Published As

Publication number Publication date
ZA200407984B (en) 2005-10-18
PE20040684A1 (es) 2004-10-05
PL373889A1 (en) 2005-09-19
TW200306183A (en) 2003-11-16
NZ535763A (en) 2007-06-29
CN1658874A (zh) 2005-08-24
CA2481940A1 (en) 2003-10-30
ATE389406T1 (de) 2008-04-15
DE60319813D1 (de) 2008-04-30
AU2003223627C1 (en) 2003-11-03
AU2003223627B2 (en) 2006-10-12
KR100827470B1 (ko) 2008-05-06
SI1499316T1 (sl) 2008-08-31
NO20045002L (no) 2005-01-18
WO2003088967A1 (en) 2003-10-30
ES2301791T3 (es) 2008-07-01
BR0309348A (pt) 2005-03-01
ECSP045367A (es) 2004-11-26
DE60319813T2 (de) 2009-04-23
CN100522166C (zh) 2009-08-05
CY1110363T1 (el) 2012-05-23
RU2323935C2 (ru) 2008-05-10
EP1499316A1 (de) 2005-01-26
AR040405A1 (es) 2005-04-06
KR20040099445A (ko) 2004-11-26
IL164584A0 (en) 2005-12-18
MXPA04010173A (es) 2005-02-03
IL164584A (en) 2010-12-30
AU2003223627A1 (en) 2003-11-03
RU2004133764A (ru) 2005-07-20
EP1499316B1 (de) 2008-03-19
JP4384918B2 (ja) 2009-12-16
JP2005529116A (ja) 2005-09-29
PT1499316E (pt) 2008-06-30
DK1499316T3 (da) 2008-07-21

Similar Documents

Publication Publication Date Title
HK1067981A1 (en) (1-4-piperidinyl) benzimidazole derivatives usefulas histamine h3 antagonists
HK1072259A1 (en) Indole derivatives useful as histamine h3 antagonists
LTPA2017027I1 (lt) (Tio)karbamoil-cikloheksano dariniai kaip D3/D2 receptorių antagonistai
IL165810A0 (en) Novel benzimidazole derivatives
IL199668A0 (en) New benzimidazole derivatives
HK1079509A1 (en) Indole or benzimidazole derivatives for modulating1 B kinase
AU2003257094A1 (en) Substituted benzimidazole compounds
IL164583A0 (en) 1-(4-Piperidinyl) benzimidazolones as histamine H3antagonists
IS7625A (is) Nýjar samrunnar imídazól afleiður
PL372295A1 (en) Quinoline derivatives as npy antagonists
ATE386518T1 (de) Benzimidazolderivate
GB0315870D0 (en) Heterocyclic derivatives
PL377609A1 (pl) Pochodne indazolu jako antagoniści CRF
PL372463A1 (en) Thiazole derivatives as npy receptor antagonists
SI1636206T1 (sl) Imidazolni derivati kot antagonisti receptorja glutamata
IS6818A (is) Histamín viðtaka mótlyf
SI1539742T1 (sl) Indolni derivati, uporabni kot antagonisti histamina H3
GB0220962D0 (en) Heterocyclic derivatives
GB0220961D0 (en) Heterocyclic derivatives
GB0209994D0 (en) heterocyclic derivatives
GB0209990D0 (en) Heterocyclic derivatives
GB0209993D0 (en) Heterocyclic derivatives
GB0206859D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120416